Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
M&A activity
confidence 95%
filed 2026-06-22
Item 7.01
PNC announced the completion of its acquisition of FirstBank (announced January 5, 2026) and the subsequent conversion of FirstBank's 780,000 customers, 1,620+ employees, and 95 branches to PNC Bank on June 22, 2026. The filing discloses the merger of FirstBank into PNC Bank on June 18, 2026, representing the final integration milestone of a material acquisition. This is a completion of M&A activity that materially affects PNC's operations and customer base.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-06-22
Item 2.05
Lucid Group announced a structured workforce reduction plan involving an 18% reduction of U.S. workforce and elimination of a production shift at AMP-1, with estimated cash charges of $32 million for severance and benefits and projected annualized cost savings of $158 million.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Marc Winterhoff, Chief Operating Officer of Lucid Group, Inc., departed the Company effective immediately following the elimination of the COO position.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-22
EX-99.1
Gold Fields discloses an ongoing material operational and regulatory matter: the renewal process for five Tarkwa mining leases due in April 2027, with early application submitted in November 2025 and ongoing engagements with the Government of Ghana focused on renewal terms. While the outcome remains uncertain, the Tarkwa mine is a material operating asset, and lease renewal is a critical operational milestone that would affect investor assessment of the company's ability to continue operations at this location. This is neither a discrete event (M&A, impairment, litigation) nor a periodic report, but rather a material operational/regulatory development requiring disclosure.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-06-22
Item 1.01
Playboy entered into a stock repurchase agreement to purchase approximately 16.6 million shares (approximately 15% of outstanding shares) at $1.05 per share for a total of approximately $17.4 million, structured in four installments through December 31, 2026. This material share-repurchase program constitutes a return of capital to shareholders and is immediately accretive to EPS.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-22
Item 5.02
The Board of Directors elected Shoshana M. Vernick as a director effective June 19, 2026, and appointed her to three board committees (Compensation, Finance and Capital Allocation, and Technology and Information Security). The disclosure centers on the appointment of a new director and her committee assignments, making this a clear exec_appointment event. The compensation details provided are incidental to the appointment itself.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
Allogene held its 2026 Annual Meeting of Stockholders on June 18, 2026, with final voting results reported for five proposals: election of three Class II directors (Messemer, Sato, Witte), advisory approval of named executive officer compensation, say-on-pay frequency (approved annually), amendment to increase authorized shares from 400 million to 800 million, and ratification of Ernst & Young LLP as independent auditor.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-06-22
Item 8.01
Allogene filed a prospectus supplement on June 22, 2026 authorizing sales of up to $135.0 million in common stock pursuant to an at-the-market (ATM) sales agreement with TD Securities, representing a material dilutive equity issuance.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 95%
filed 2026-06-22
Item 8.01
SkinHealth Systems disclosed settlement of a securities class action (Alghazwi v. The Beauty Health Company, Case No. 2:23-cv-09733-SPG-MAA) with a total cash settlement of $18 million, of which the Company will pay $3 million from its own funds. This is a material litigation settlement that would affect a reasonable investor's assessment of the registrant's financial condition and contingent liabilities, disclosed under Item 8.01 (Other Events) as required for material litigation matters.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear disclosure of shareholder voting results from OPAL Fuels' 2026 Annual Meeting of Stockholders held on June 17, 2026. The filing presents detailed voting tallies for two proposals: election of eight directors and ratification of BDO USA, P.C. as independent auditor. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly reports the FOR/WITHHELD/AGAINST votes cast on each matter.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Dr. Noah Berkowitz, the Company's chief medical officer, is departing effective July 3, 2026. While the disclosure includes severance terms (base salary continuation, health coverage, and RSU acceleration), the principal disclosed action is the departure of a named executive officer from his role. The filing centers on the departure event and the separation agreement executed in connection with it.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear disclosure of shareholder voting results from National Vision's June 17, 2026 annual meeting of stockholders. The filing presents the outcomes of three proposals: election of eleven directors, advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor. Item 5.07 is the designated 8-K item for shareholder vote results, and the prose directly reports vote tallies (For, Against, Abstain, Broker Non-Vote) for each proposal, which is the standard format for this event type.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-22
Item 5.02
The filing discloses the appointment of Douglas Britt to TD SYNNEX's Board of Directors effective June 17, 2026, with assignment to the Audit Committee and Technology Committee. The principal disclosed action is a person taking a governance role. While the disclosure includes standard compensation details for newly appointed non-employee directors, the core event is the board appointment itself, making exec_appointment the most salient classification. This is material as board composition changes affect corporate governance and oversight.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-06-22
Item 1.01
Ares Capital amended its BNP Funding Facility, increasing total commitments by $200 million from $1.265 billion to $1.465 billion, representing a material expansion of the registrant's borrowing capacity and direct financial obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of GRAIL's Annual Meeting of Stockholders held on June 18, 2026. The filing presents voting results for two proposals: election of two Class II Directors (Sarah Krevans and Steven Mizell) and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (votes for, withheld, broker non-votes, and abstentions) are the core content of the disclosure, making this unambiguously a shareholder_vote_results event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-06-22
Item 8.01
The filing discloses two material listing compliance failures: (1) stockholders' equity of $9.0 million fell below the $10 million Nasdaq Global Market minimum, triggering a transfer to Nasdaq Capital Market effective June 23, 2026; and (2) the stock price has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, with an initial 180-day cure period ending September 14, 2026. The company explicitly acknowledges "there can be no assurance that the Company will be able to regain compliance," creating a material delisting risk that would substantially affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Other material
confidence 72%
filed 2026-06-22
The filing discloses S&P Global Ratings' upgrade of Bladex's long-term issuer credit rating from 'BBB' to 'BBB+' and affirmation of short-term rating at 'A-2', with stable outlook. While this is a material credit-rating event that would affect investor assessment of the registrant's creditworthiness and financial standing, it does not fit neatly into the standard 8-K taxonomy (no dedicated category for credit-rating upgrades). The domain is clearly financial, but the specific event type is not a named category, making `other_material` the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-22
Item 5.02
Blair Aiken was elected by the Board effective June 15, 2026 to serve as President, interim CEO, Board Member, and Chairman of the Board. While the filing also discloses that Benjamin Jennings departed as Chairman, the principal disclosed action centers on Aiken's appointment to multiple leadership roles, including the critical interim CEO position. This is material as it represents a significant change in executive leadership during a strategic combination with Rain Cage Carbon, Inc.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-22
Item 5.07
This Item 5.07 disclosure reports the results of an annual stockholder meeting held on June 17, 2026, where shareholders voted on two proposals: (1) election of Phil Garfinkle as a Class II director and (2) ratification of Baker Tilly US, LLP as independent accountants for fiscal year 2026. Both votes are routine governance matters with clear voting tallies, making this a straightforward shareholder_vote_results classification.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-06-22
The disclosure announces a new CEO contract for Michael O'Leary extending to April 2032, including a modest annual salary, capped annual bonus, and a one-off equity purchase option over 10 million shares with performance-based vesting conditions tied to PAT growth (€4.0bn) or share price targets (€42 or $102). This is a material compensatory arrangement for a named executive officer that would affect investor assessment of executive incentives and long-term leadership continuity.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-06-22
This 6-K discloses a grant of 10 million share options to Michael O'Leary, Group Chief Executive Officer, at a strike price of €26.70 under the Ryanair Holdings plc 2019 Long Term Incentive Plan. This is a compensatory arrangement for a named executive officer and falls squarely within exec_compensation disclosure requirements under Article 19 of the EU Market Abuse Regulation. The materiality is high given the size of the grant (10 million options) and the executive's senior position.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 93%
filed 2026-06-22
Item 3.02
Data I/O closed a $9 million private placement on June 17, 2026, issuing 869,840 shares of common stock, convertible debentures ($6.8 million principal at 4.0% annual interest, maturing in five years and convertible into Series B preferred stock), and warrants to purchase 1,080,000 shares. The unregistered securities sale represents a material capital raise with significant equity dilution to existing shareholders, including potential conversion of debentures into approximately 2.73 million common shares and warrant overhang.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear disclosure of shareholder vote results from Cronos Group's 2026 Annual Meeting of Shareholders held on June 18, 2026, covering four proposals: election of seven directors, advisory approval of named executive officer compensation, frequency of say-on-pay votes, and appointment of the independent auditor. The filing presents final voting tallies for each proposal, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This 8-K Item 5.07 discloses the final voting results from Crinetics Pharmaceuticals' annual stockholder meeting held June 18, 2026, covering three proposals: election of three Class II directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. The filing presents complete vote tallies (For, Against/Withheld, Abstentions, and Broker Non-Votes) for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-06-22
Item 8.01
YHN Acquisition I Limited, a SPAC, deposited $150,000 into its trust account to extend the business combination deadline from June 19, 2026 to September 19, 2026. This is a governance and structural matter related to the SPAC's timeline and trust account management. While material to shareholders as it affects the window for completing a business combination, it does not fit neatly into specific event categories like M&A activity (no combination announced or completed) or other named types, making governance_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Restatement
confidence 98%
filed 2026-06-22
Item 4.02
The filing explicitly discloses non-reliance on previously issued unaudited interim financial statements for the quarters ended August 31, 2024 and November 30, 2024, due to the failure to reflect 50,850,000 shares issued on June 5, 2024 and related stock-based compensation under ASC 718. The Company is restating these financial statements via amended 10-Q/A filings. This is a classic restatement disclosure under Item 4.02, driven by accounting errors in share issuance and stock-based compensation recognition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This Item 5.07 disclosure reports the results of Inseego Corp.'s June 16, 2026 annual stockholder meeting, including voting outcomes for three proposals: election of two directors (James B. Avery and Jeffrey Tuder), ratification of CBIZ CPAs P.C. as independent auditors, and an advisory vote on executive compensation. The filing presents vote tallies (For, Against, Abstentions, Broker Non-Votes) for each proposal, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Delta Air Lines' 2026 Annual Meeting of Shareholders held on June 18, 2026. The filing presents voting results for five proposals: election of fourteen directors, advisory vote on executive compensation, ratification of Ernst & Young LLP as independent auditors, and two shareholder proposals (written consent and cumulative voting). The detailed vote tallies for each matter are the core content of the disclosure, making this unambiguously a shareholder vote results event.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-06-22
Item 2.02
Tianci International announced financial results for the fiscal quarter ended April 30, 2026, via press release filed as Exhibit 99.1. The company reported 121% quarter-to-quarter revenue growth, a swing from a net loss of $959,409 in the prior-year quarter to net income of $91,545, and expansion into mineral ore trading.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-06-22
Item 4.01
The Company dismissed Fruci & Associates II, PLLC as its independent registered public accounting firm on June 17, 2026, and appointed Grassi & Co., CPAs, P.C. as the new auditor on the same date. No disagreements, adverse opinions, or reportable events were noted in connection with the transition.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-22
Item 5.07
The majority stockholder (Hawkeye Holdco, LLC, holding 90.1% of voting power) approved by written consent multiple fundamental corporate actions: a name change to Hawkeye Digital, Inc., an increase in authorized shares from 450 million to 10.05 billion, a reclassification of the Board into three classes, authorization for a reverse stock split (1-for-2 to 1-for-20), and adoption of an Equity Incentive Plan. These structural changes materially affect the company's capital structure and governance.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-06-22
Item 5.02
Stockholders approved the Hawkeye Digital, Inc. 2026 Equity Incentive Plan, a compensatory arrangement designed to provide equity incentives to employees, consultants, and directors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-22
Item 8.01
Praxis announced FDA Breakthrough Therapy Designation for elsunersen (PRAX-222) for SCN2A-DEE, supported by positive Phase 1/2 trial results. This is a material regulatory milestone that accelerates development and review timelines for a lead candidate, directly affecting the company's clinical and commercial prospects. While not fitting a specific named category, this is clearly an operational/strategic event material to investors assessing the registrant's pipeline progress.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
This Item 3.02 disclosure describes an unregistered private placement of preferred stock under Regulation D Rule 506(b) to accredited investors. The Company issued 208,797 shares of Series 2025 Preferred Stock during the period June 3–21, 2026, raising approximately $2.08 million in aggregate proceeds. As of the filing date, 11.9 million shares of this series were outstanding, indicating a substantial ongoing capital raise. This is a classic dilutive equity issuance material to investors assessing the registrant's capital structure and ownership dilution.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-22
Item 7.01
The filing discloses a declaration of distributions to stockholders across five classes of common stock (Class T, S, D, I, and N), with specific per-share amounts and payment details. This is a routine but material dividend distribution event typical of REITs, which are required to distribute substantially all taxable income to shareholders. The disclosure includes gross distributions, fee deductions, net distributions per share, record date, and payment date information.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-06-22
EX-99.1
This press release discloses unaudited operating revenue figures for a newly launched business segment (Smart Campus Services): approximately US$9.49 million cumulative revenue since September 2025 launch through May 31, 2026, with US$3.83 million in April–May 2026 alone. Although the figures are explicitly unaudited and not prepared under U.S. GAAP, the disclosure of material revenue metrics for a significant new business line constitutes a substantive financial announcement that would affect a reasonable investor's assessment of the company's growth trajectory and business diversification. The CEO's statement emphasizing this as "one of the operating businesses that we believe can define the Company's next stage of growth" reinforces materiality. The confidence is moderate (0.75) because the unaudited nature and explicit caveats about audit adjustments and revenue-recognition differences create some ambiguity about whether this rises to the level of a formal earnings release versus an operational announcement.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-06-22
Item 1.01
Arcosa entered into an Agreement and Plan of Merger with CRH Americas on June 21, 2026, whereby Arcosa will be acquired for $150 per share in an all-cash transaction valued at approximately $8.5 billion. The transaction represents a change of control and is subject to customary closing conditions including stockholder approval and regulatory clearances, with an expected closing in Q1 2027.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Jeffrey Horowitz, Chief Compliance Officer, gave notice of retirement effective June 19, 2026. The filing explicitly states his departure was not due to disagreement with the Company. This is a straightforward executive departure of a named officer in a compliance-critical role, material to investor assessment of the registrant's governance and risk management structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Monroe Capital issued 1,222,087 shares of common stock at $9.77 per share for aggregate proceeds of $11.9 million pursuant to subscription agreements, with the sale exempt from registration under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-06-22
Item 8.01
The board declared a dividend distribution of $0.068 per share to stockholders of record as of June 23, 2026, payable on or about June 25, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-06-22
Item 2.02
HawkEye 360 issued a press release on June 22, 2026 announcing financial results for Q1 2026, disclosing record revenue of $49.8 million (up 116.5% YoY), a net loss of $(9.0) million, record adjusted EBITDA of $7.4 million, and a backlog of $285.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. This is a material disclosure affecting investor assessment of the registrant's financial performance and growth trajectory.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-06-22
Item 7.01
The disclosure reports closure of a DOJ Antitrust Division grand jury investigation into health insurance practices, with the Company cleared of criminal investigation, but simultaneously reveals an ongoing civil investigative demand from the same division. This is a material legal/regulatory event involving government investigation that does not fit a specific named category (not litigation, not a settlement, not a covenant breach). The dual nature—closure of criminal inquiry but continuation of civil investigation—represents a significant regulatory development affecting the Company's legal exposure and business operations in healthcare.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This Item 5.07 disclosure reports the results of Butterfly Network's 2026 Annual Meeting of Stockholders held on June 18, 2026, with detailed voting tallies for three proposals: (1) election of seven directors, (2) ratification of Deloitte & Touche LLP as independent auditor, and (3) advisory vote on named executive officer compensation. The filing explicitly states the vote counts for each proposal, which is the core content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-22
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from the Company's June 18, 2026 annual meeting of stockholders. The filing reports voting outcomes on three proposals: election of two Class II directors (Neil Glat and Richard Shapiro), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditor. All proposals passed. This is material as it reflects shareholder governance decisions and auditor ratification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-22
Item 3.02
Blue Owl Credit Income Corp. completed an unregistered private placement sale of 527,106 shares of Class I common stock for approximately $4.8 million, exempt under Section 4(a)(2) and Regulation S, to feeder vehicles created to hold the Company's Class I shares.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-06-22
Item 8.01
The board declared monthly distributions to shareholders across three share classes (Class S, D, and I) on May 5, 2026, with specific gross and net distribution amounts per share payable by July 31 and August 31, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-22
Item 5.02
The Board elected Barry E. Greene as a Class I director on June 22, 2026. The disclosure centers on the appointment of a new director to the Board, including his compensation package (option grant of 57,463 shares at $20.87 and annual cash compensation of $45,000). This is a clear director appointment under Item 5.02, which is material to investors as it affects Board composition and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-06-22
Item 1.01
BuzzFeed entered into two share purchase agreements on June 17–18, 2026, selling 4,216,999 shares of Class A common stock (including 2,173,155 newly issued shares) at $1.44 per share for approximately $5.8 million in aggregate proceeds, pursuant to Section 4(a)(2) exemption from Securities Act registration. The transaction materially dilutes existing shareholders and raises capital at a modest valuation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-22
Item 5.02
TaskUs appointed Rishabh Khemka as Chief Financial Officer effective June 19, 2026, succeeding interim CFO Trent Thrash who transitions to SVP of Corporate Development, Investor Relations and Treasury. The appointment includes detailed compensation arrangements including base salary, bonus, sign-on bonus, and equity grants.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-22
Item 1.01
Sable Offshore amended its Senior Secured Term Loan Agreement with Exxon, extending the maturity date to July 24, 2026, suspending the $25 million minimum liquidity covenant, and waiving P&A Financial Security obligations, while agreeing to pay a $30 million amendment fee. The company also announced plans to enter into a new $775 million Senior Secured Term Loan to refinance the existing facility, representing material debt refinancing activity.
View raw filing on EDGAR →